Literature DB >> 12699009

Mucosal immunity and vaccination against HIV.

Thomas Lehner1, Peter A Anton.   

Abstract

Mesh：

Substances：

Year:  2002        PMID： 12699009     DOI： 10.1097/00002030-200216004-00017

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  16 in total

Review 1.  Mechanisms of HSP72 release.

Authors:  Alexzander Asea
Journal:  J Biosci       Date:  2007-04       Impact factor: 1.826

2.  Effects of different routes of administration on the immunogenicity of the Tat protein and a Tat-derived peptide.

Authors:  Valentina Finessi; Francesco Nicoli; Eleonora Gallerani; Fabio Sforza; Mariaconcetta Sicurella; Aurelio Cafaro; Antonella Caputo; Barbara Ensoli; Riccardo Gavioli
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Divergent HIV-1-Directed Immune Responses Generated by Systemic and Mucosal Immunization with Replicating Single-Cycle Adenoviruses in Rhesus Macaques.

Authors:  William E Matchett; Stephanie S Anguiano-Zarate; Pramod N Nehete; Kathryn Shelton; Bharti P Nehete; Guojun Yang; Stephanie Dorta-Estremera; Philip Barnette; Peng Xiao; Siddappa N Byrareddy; Francois Villinger; Ann J Hessell; Nancy L Haigwood; K Jagannadha Sastry; Michael A Barry
Journal:  J Virol       Date:  2019-05-01       Impact factor: 5.103

4.  Sublingual injection of microparticles containing glycolipid ligands for NKT cells and subunit vaccines induces antibody responses in oral cavity.

Authors:  Elizabeth S DeLyria; Dapeng Zhou; Jun Soo Lee; Shailbala Singh; Wei Song; Fenge Li; Qing Sun; Hongzhou Lu; Jinhui Wu; Qian Qiao; Yiqiao Hu; Guodong Zhang; Chun Li; K Jagannadha Sastry; Haifa Shen
Journal:  Carbohydr Res       Date:  2014-12-03       Impact factor: 2.104

Review 5.  Chaperokine-induced signal transduction pathways.

Authors:  Alexzander Asea
Journal:  Exerc Immunol Rev       Date:  2003       Impact factor: 6.308

6.  Protection against Mucosal SHIV Challenge by Peptide and Helper-Dependent Adenovirus Vaccines.

Authors:  Eric A Weaver; Pramod N Nehete; Bharti P Nehete; Stephanie J Buchl; Donna Palmer; David C Montefiori; Philip Ng; K Jagannadha Sastry; Michael A Barry
Journal:  Viruses       Date:  2009-12-01       Impact factor: 5.048

7.  Differential immunogenicity of vaccinia and HIV-1 components of a human recombinant vaccine in mucosal and blood compartments.

Authors:  Peter A Anton; F Javier Ibarrondo; W John Boscardin; Ying Zhou; Elissa J Schwartz; Hwee L Ng; Mary Ann Hausner; Roger Shih; Julie Elliott; Patricia M Hultin; Lance E Hultin; Charles Price; Marie Fuerst; Amy Adler; Johnson T Wong; Otto O Yang; Beth D Jamieson
Journal:  Vaccine       Date:  2008-06-17       Impact factor: 3.641

8.  Alpha-galactosylceramide is an effective mucosal adjuvant for repeated intranasal or oral delivery of HIV peptide antigens.

Authors:  Amy N Courtney; Pramod N Nehete; Bharti P Nehete; Prakash Thapa; Dapeng Zhou; K Jagannadha Sastry
Journal:  Vaccine       Date:  2009-02-05       Impact factor: 3.641

9.  T-cell-biased immune responses generated by a mucosally targeted adenovirus-σ1 vaccine.

Authors:  E A Weaver; G T Mercier; S Gottschalk; M A Barry
Journal:  Mucosal Immunol       Date:  2012-02-29       Impact factor: 7.313

10.  CCL28 induces mucosal homing of HIV-1-specific IgA-secreting plasma cells in mice immunized with HIV-1 virus-like particles.

Authors:  Veronica Rainone; Gregor Dubois; Vladimir Temchura; Klaus Überla; Alberto Clivio; Manuela Nebuloni; Eleonora Lauri; Daria Trabattoni; Francisco Veas; Mario Clerici
Journal:  PLoS One       Date:  2011-10-31       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.